The IBTA’s monthly e-News has been released and has emailed to all subscribers. Emailed to over 5,000 people around the globe, including clinicians, patients, researchers and others, it gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
This month’s highlights
You can read the IBTA e-News January 2024 edition in full online here.
Some highlights from this month’s round-up:
- The Centre for International Economics in Australia has published a mid-term review of the Australian Brain Cancer Mission‘s progress. The ten-year (2017-2027) initiative has made substantial progress in research funding, clinical trial access for 1,350 patients, and advancements in translational and survivorship research, the report has found.
- A multicentre, international Phase II trial, EORTC 1636 / NOA-23 (PersoMed-l ) looking for the most effective treatment with the fewest side effects in adolescent (post-pubertal) and adult patients with medulloblastomas is now recruiting. Taking across place across Europe and Australia, more information can be found here.
- A blood-based test for glioma has been the subject of a clinical validation study, published in the International Journal of Cancer. Four clinical studies showed 100% specificity and 99.35% sensitivity.
- A study published in Cancer Cell has found that glioblastoma cells transition to neuron-like states to evade treatment, mimicking normal brain cells.
- Writing in Scientific Reports, a team of researchers have detailed a large language model (a type of AI, artificial intelligence) called GlioPredictor, which can help predict glioma early progression.
- NovoCure has announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® (formerly known as Optune®).
To see an archive of existing e-News issues, click here.
Sign up to receive the e-News every month by registering here.
